Larry Biegelsen
Stock Analyst at Wells Fargo
(4.32)
# 480
Out of 4,496 analysts
204
Total ratings
60.41%
Success rate
12.11%
Average return
Main Sectors:
31 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GKOS Glaukos | Maintains: Overweight | $110 → $120 | $120.73 | -0.60% | 9 | Jun 3, 2024 | |
| MDT Medtronic | Maintains: Overweight | $102 → $105 | $79.48 | +32.11% | 12 | May 24, 2024 | |
| ALC Alcon | Maintains: Overweight | $89 → $94 | $90.01 | +4.43% | 5 | May 15, 2024 | |
| RXST RxSight | Maintains: Overweight | $61 → $68 | $46.77 | +45.39% | 6 | May 7, 2024 | |
| TNDM Tandem Diabetes Care | Maintains: Overweight | $45 → $50 | $43.66 | +14.52% | 6 | May 3, 2024 | |
| SYK Stryker | Maintains: Overweight | $364 → $381 | $340.95 | +11.75% | 9 | May 1, 2024 | |
| NARI Inari Medical | Maintains: Overweight | $100 → $84 | $54.90 | +53.01% | 3 | May 1, 2024 | |
| EW Edwards Lifesciences | Maintains: Overweight | $94 → $99 | $86.50 | +14.45% | 12 | Apr 26, 2024 | |
| BSX Boston Scientific | Maintains: Overweight | $72 → $82 | $77.56 | +5.72% | 5 | Apr 25, 2024 | |
| NVRO Nevro | Maintains: Equal-Weight | $17 → $14 | $9.10 | +53.85% | 7 | Apr 8, 2024 | |
| NVCR NovoCure | Maintains: Overweight | $49 → $42 | $18.40 | +128.26% | 15 | Apr 3, 2024 | |
| HYPR Hyperfine | Maintains: Equal-Weight | $2.1 → $1.6 | $1.21 | +32.78% | 3 | Mar 22, 2024 | |
| LUNG Pulmonx | Downgrades: Equal-Weight | $16 → $14 | $7.92 | +76.77% | 4 | Feb 23, 2024 | |
| BLCO Bausch + Lomb | Maintains: Overweight | $21 → $23 | $16.98 | +35.45% | 2 | Feb 22, 2024 | |
| ISRG Intuitive Surgical | Maintains: Overweight | $363 → $416 | $455.01 | -8.57% | 13 | Jan 19, 2024 | |
| AXNX Axonics | Downgrades: Equal-Weight | $68 → $71 | $67.72 | +4.84% | 4 | Jan 10, 2024 | |
| DXCM DexCom | Maintains: Overweight | $110 → $136 | $111.66 | +21.80% | 6 | Dec 13, 2023 | |
| INSP Inspire Medical Systems | Downgrades: Equal-Weight | $187 | $143.74 | +30.10% | 4 | Dec 13, 2023 | |
| JNJ Johnson & Johnson | Downgrades: Equal-Weight | $170 → $163 | $154.69 | +5.37% | 9 | Dec 13, 2023 | |
| IART Integra LifeSciences Holdings | Upgrades: Overweight | $40 → $49 | $31.34 | +56.35% | 2 | Dec 5, 2023 | |
| GEHC GE HealthCare Technologies | Initiates: Overweight | $90 | $80.44 | +11.88% | 1 | Aug 16, 2023 | |
| TFX Teleflex | Maintains: Equal-Weight | $241 → $236 | $221.79 | +6.41% | 3 | Aug 4, 2023 | |
| PEN Penumbra | Maintains: Overweight | $320 → $337 | $189.87 | +77.49% | 9 | Aug 2, 2023 | |
| BAX Baxter International | Maintains: Equal-Weight | $46 → $44 | $35.35 | +24.47% | 7 | Jul 28, 2023 | |
| COO The Cooper Companies | Maintains: Overweight | $89 → $108 | $90.75 | +18.46% | 13 | May 15, 2023 | |
| MMSI Merit Medical Systems | Maintains: Equal-Weight | $74 → $81 | $85.49 | -5.25% | 4 | Apr 27, 2023 | |
| ABT Abbott Laboratories | Maintains: Overweight | $140 → $136 | $102.03 | +33.29% | 18 | Apr 5, 2023 | |
| ZBH Zimmer Biomet Holdings | Upgrades: Equal-Weight | $116 → $124 | $110.50 | +12.22% | 5 | Nov 23, 2022 | |
| GMED Globus Medical | Maintains: Overweight | $80 → $70 | $72.63 | -3.62% | 4 | May 11, 2022 | |
| BDX Becton, Dickinson and Company | Maintains: Overweight | n/a | $230.74 | - | 3 | Apr 8, 2020 | |
| LNTH Lantheus Holdings | Upgrades: Outperform | n/a | $116.79 | - | 1 | Nov 2, 2017 |
Glaukos
Jun 3, 2024
Maintains: Overweight
Price Target: $110 → $120
Current: $120.73
Upside: -0.60%
Medtronic
May 24, 2024
Maintains: Overweight
Price Target: $102 → $105
Current: $79.48
Upside: +32.11%
Alcon
May 15, 2024
Maintains: Overweight
Price Target: $89 → $94
Current: $90.01
Upside: +4.43%
RxSight
May 7, 2024
Maintains: Overweight
Price Target: $61 → $68
Current: $46.77
Upside: +45.39%
Tandem Diabetes Care
May 3, 2024
Maintains: Overweight
Price Target: $45 → $50
Current: $43.66
Upside: +14.52%
Stryker
May 1, 2024
Maintains: Overweight
Price Target: $364 → $381
Current: $340.95
Upside: +11.75%
Inari Medical
May 1, 2024
Maintains: Overweight
Price Target: $100 → $84
Current: $54.90
Upside: +53.01%
Edwards Lifesciences
Apr 26, 2024
Maintains: Overweight
Price Target: $94 → $99
Current: $86.50
Upside: +14.45%
Boston Scientific
Apr 25, 2024
Maintains: Overweight
Price Target: $72 → $82
Current: $77.56
Upside: +5.72%
Nevro
Apr 8, 2024
Maintains: Equal-Weight
Price Target: $17 → $14
Current: $9.10
Upside: +53.85%
NovoCure
Apr 3, 2024
Maintains: Overweight
Price Target: $49 → $42
Current: $18.40
Upside: +128.26%
Hyperfine
Mar 22, 2024
Maintains: Equal-Weight
Price Target: $2.1 → $1.6
Current: $1.21
Upside: +32.78%
Pulmonx
Feb 23, 2024
Downgrades: Equal-Weight
Price Target: $16 → $14
Current: $7.92
Upside: +76.77%
Bausch + Lomb
Feb 22, 2024
Maintains: Overweight
Price Target: $21 → $23
Current: $16.98
Upside: +35.45%
Intuitive Surgical
Jan 19, 2024
Maintains: Overweight
Price Target: $363 → $416
Current: $455.01
Upside: -8.57%
Axonics
Jan 10, 2024
Downgrades: Equal-Weight
Price Target: $68 → $71
Current: $67.72
Upside: +4.84%
DexCom
Dec 13, 2023
Maintains: Overweight
Price Target: $110 → $136
Current: $111.66
Upside: +21.80%
Inspire Medical Systems
Dec 13, 2023
Downgrades: Equal-Weight
Price Target: $187
Current: $143.74
Upside: +30.10%
Johnson & Johnson
Dec 13, 2023
Downgrades: Equal-Weight
Price Target: $170 → $163
Current: $154.69
Upside: +5.37%
Integra LifeSciences Holdings
Dec 5, 2023
Upgrades: Overweight
Price Target: $40 → $49
Current: $31.34
Upside: +56.35%
GE HealthCare Technologies
Aug 16, 2023
Initiates: Overweight
Price Target: $90
Current: $80.44
Upside: +11.88%
Teleflex
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $241 → $236
Current: $221.79
Upside: +6.41%
Penumbra
Aug 2, 2023
Maintains: Overweight
Price Target: $320 → $337
Current: $189.87
Upside: +77.49%
Baxter International
Jul 28, 2023
Maintains: Equal-Weight
Price Target: $46 → $44
Current: $35.35
Upside: +24.47%
The Cooper Companies
May 15, 2023
Maintains: Overweight
Price Target: $89 → $108
Current: $90.75
Upside: +18.46%
Merit Medical Systems
Apr 27, 2023
Maintains: Equal-Weight
Price Target: $74 → $81
Current: $85.49
Upside: -5.25%
Abbott Laboratories
Apr 5, 2023
Maintains: Overweight
Price Target: $140 → $136
Current: $102.03
Upside: +33.29%
Zimmer Biomet Holdings
Nov 23, 2022
Upgrades: Equal-Weight
Price Target: $116 → $124
Current: $110.50
Upside: +12.22%
Globus Medical
May 11, 2022
Maintains: Overweight
Price Target: $80 → $70
Current: $72.63
Upside: -3.62%
Becton, Dickinson and Company
Apr 8, 2020
Maintains: Overweight
Price Target: n/a
Current: $230.74
Upside: -
Lantheus Holdings
Nov 2, 2017
Upgrades: Outperform
Price Target: n/a
Current: $116.79
Upside: -